Upper airway stimulation (UAS) with the Inspire hypoglossal nerve stimulator has established itself as the most effective surgical intervention for CPAP-intolerant obstructive sleep apnea since the STAR trial results were published in 2014. The therapy delivers mild electrical stimulation to the hypoglossal nerve during inspiration, advancing the tongue to prevent upper airway collapse. Now in its fifth generation, Inspire V incorporates a decade of engineering refinements into a system that is smaller, smarter, more MRI-compatible, and accessible to a broader patient population than any previous iteration.
What's New in Inspire V
FDA approval of Inspire V was granted in Q3 2025. Key improvements over the previous generation:
- Smaller IPG (implantable pulse generator): 28% volume reduction, now 27cc — comparable to a cardiac pacemaker. Reduced subcutaneous profile improves cosmesis and patient comfort.
- Full-body 3T MRI compatibility: Previous generations were limited to 1.5T in specific body regions. Inspire V is conditionally approved for full-body 3T scanning, resolving a major limitation for patients who require ongoing MRI surveillance.
- Bluetooth automatic titration: The new Inspire Sleep app synchronizes with the IPG via Bluetooth, and an AI algorithm analyzes nightly usage data to automatically suggest titration adjustments — previously requiring a physician-attended titration appointment.
- Expanded eligibility: BMI limit raised from 32 to 35; complete concentric collapse at palate on DISE (previously a contraindication) now manageable with modified stimulation parameters.
- Longer battery longevity: Estimated 12–14 years vs 10–12 for the previous generation.
Five-Year Outcomes: The ADHERE Registry
The ADHERE (Adherence and Outcome of Upper Airway Stimulation for OSA) registry, now including over 4,800 patients from 100+ centers across the US and Europe, published 5-year follow-up data in JAMA Otolaryngology in early 2026:
- Mean AHI reduction: 79% from baseline (from 34.2 to 7.1 events/hour)
- Responder rate (≥50% AHI reduction + AHI <20): 83% at 5 years
- Nightly usage: Mean 7.2 hours/night — dramatically higher than CPAP adherence in the same AHI range
- Epworth Sleepiness Scale: Sustained improvement from 11.5 to 6.8
- Serious adverse events: 3.2% over 5 years, primarily infection (1.8%) and IPG pocket discomfort requiring revision (1.1%)
Patient Selection in 2026
Drug-induced sleep endoscopy (DISE) remains mandatory for patient selection, identifying the collapse pattern that predicts UAS response. With the expanded BMI limit to 35 and revised DISE criteria, an estimated 4.5 million additional US patients now meet Inspire eligibility criteria who previously did not. Combined with the OSA indication for tirzepatide, the CPAP-intolerant patient now has meaningful treatment options for the first time in OSA's history as a defined disease.
The Combination Approach: Inspire + Tirzepatide
A growing number of sleep medicine centers are using Inspire UAS and tirzepatide together in patients with severe obesity and severe OSA. Early case series suggest the combination produces AHI reductions approaching 90% from baseline, with weight loss additionally reducing titration requirements and improving surgical anatomy over time. Formal randomized trial data is anticipated in 2027.
Conclusion
Inspire V is the most refined and accessible iteration of an already proven technology. The combination of better hardware, MRI compatibility, expanded eligibility, and AI-assisted titration positions hypoglossal nerve stimulation for substantially broader adoption in the growing population of patients who need effective OSA treatment beyond what CPAP can provide. Healthcare facilities can find relevant diagnostic equipment in our catalog.
